Proactive Investors - Run By Investors For Investors

Pharmaxis advancing partnership talks for LOXL2, starting pancreatic cancer program

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips updates Proactive Investors on the pharmaceutical research company’s key programs, including the latest on the anti fibrotic LOXL2 program which should be partnered on next year.

A partnership with Boehringer Ingelheim is progressing well, with representatives visiting Australia this week to update on Phase II Clinical Trials in diabetic retinopathy and NASH. Presentations given by Pharmaxis and Boehringer Ingelheim representatives may be found on the Pharmaxis website.

Phillips also discusses the company's latest move into pancreatic cancer.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use